These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

905 related articles for article (PubMed ID: 19233423)

  • 1. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
    Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
    Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M; Weiss H; Seidman L
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC; Chih SY; Chen MC
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi T; Yamaguchi O
    Int J Urol; 2008 Sep; 15(9):809-15. PubMed ID: 18637156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study.
    Goldfischer ER; Sand PK; Thomas H; Peters-Gee J
    Neurourol Urodyn; 2015 Jan; 34(1):37-43. PubMed ID: 24133005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.